510(k) Report

FDA applicant

Datar Cancer Genetics Private Limited

Nasik, IN1 decision2026–20260 recalls

FDA records 1 decision for Datar Cancer Genetics Private Limited (Nasik, IN) in 2026: 1 510(k) clearance. All are in product code PZM (Next Generation Sequencing Based Tumor…). Its devices cite 1 predicate, 0 of them its own earlier devices. No recall is linked to its devices.

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) refreshed weekly, last Nov 3, 2026

FIG. A — Illustration, pathology panel, where it files most

How often FDA has decided Datar Cancer Genetics Private Limited’s devices, and how often a recall has named them.

FDA decisions per year

1in 2026

2026 (partial year): 1
2026high 1 (2026)2026

2026 so far, outlined.

Recalls per year

No recall linked to its devices since 2026.

FIG. 1 — Datar Cancer Genetics Private Limited by year, 2026–2026Sources: FDA decision databases, recall and enforcement reports · Data through Oct 25, 2026

Planning a device like Datar Cancer Genetics Private Limited’s? A 510(k) Report ranks candidate predicates for your device by lineage, citations and recall history, with the review-time outlook.

See the 510(k) Report

Which product codes does it file in?

  • PZMNext Generation Sequencing Based Tumor Profiling Test1decision

Whose devices does it build on?

Its devices cite 1 predicate; 0 are its own earlier devices. The firms it cites most:

What has FDA decided for it lately?

  • K260235CellDx-TissueDatar Cancer Genetics Private Limited · 2026

The one decision as Datar Cancer Genetics Private Limited →